Summary Elevated circulating alanine aminotransferase (ALT) and ␥ -glutamyltransferase ( ␥ -GTP) activities, and the accumulation of fat, particularly visceral fat, in healthy and preclinical subjects reportedly increase the risk for metabolic diseases such as diabetes. In the present study, we examined the associations between these hepatic enzymes and the total visceral and subcutaneous fat area, and for both regions of fat independently, in healthy and preclinical middle-aged Japanese men. We conducted a cross-sectional study of men who participated in health check-ups in Japan. We removed participants, who were diagnosed with metabolic diseases at the time of the health check-up. Three hundred fifteen subjects aged 40-64 y (mean Ϯ SD, 50.5 Ϯ 6.9 y) were selected. We compared associations between the total visceral and subcutaneous fat area, and for both regions independently, with various clinical parameters, including hepatic enzyme markers, using Spearman's rank correlation coefficient analysis and multiple linear regression analysis. The total visceral and subcutaneous fat area and both regions independently were positively associated with body mass index, systolic and diastolic blood pressure, fasting blood glucose, total cholesterol, low-density lipoprotein cholesterol, aspartate aminotransferase, ALT and ␥ -GTP. ALT and ␥ -GTP activities were the strongest explanatory variables for increased visceral fat area, independent of the subcutaneous fat area. In contrast, these hepatic enzymes were not explanatory variables for increased subcutaneous fat area. The results of the present study show that the accumulation of visceral fat is positively associated with ALT and ␥ -GTP activities independently of subcutaneous fat area in healthy and preclinical Japanese men. Key Words ALT, ␥ -GTP, visceral fat, Japanese men, healthy and preclinical subjects Abnormalities in metabolic parameters such as hyperglycemia and lipid levels promote the development of diabetes, metabolic syndrome and related complications such as cardiovascular disease, hypertension and inflammation in peripheral tissues ( 1-3 ). Thus, it is necessary to identify biomarkers that can predict the development of these diseases. Recent studies have demonstrated that the circulating activity of ␥ -glutamyltransferase ( ␥ -GTP), a hepatic enzyme that is considered to represent liver injury and hepatic disorders, is a marker for inflammation and oxidative stress in healthy and preclinical subjects. This is because the circulating ␥ -GTP activity is closely associated with oxidative stress markers (e.g., lipid peroxides) and the inflammatory marker C-reactive protein (CRP) in healthy subjects in Western countries and in Japan, and because ␥ -GTP itself contributes to the production of reactive oxygen species (ROS) ( 4-8 ). In addition, the circulating activity of alanine aminotransferase (ALT), another hepatic enzyme marker for liver injury, is associated with liver insulin resistance in subjects in Western countries and in Japan ( 9-11 ). It has been reported that the circulating ␥ -GTP and ALT activities are associated with circulating CRP and lipid peroxides in healthy subjects, and that elevations in the activities of both ALT and ␥ -GTP are more strongly associated with elevated levels of circulating CRP and lipid peroxides, as compared with elevations in ALT or ␥ -GTP alone, independently of metabolic syndrome ( 4 ). Furthermore, several studies have demonstrated that the subsequent incidence of diabetes was greater in healthy and preclinical subjects in Western and Asian countries, including Japan, with elevated circulating ␥ -GTP and/or ALT activities within the normal range, or without fatty liver or hepatic dysfunction, as compared with subjects with lower levels of these enzymes ( 9 , 12-15 ). These results indicate that elevations in circulating ␥ -GTP and ALT activities, without fatty liver or hepatic dysfunction, in healthy and preclinical subjects may predict the future development of diabetes, metabolic syndrome and related diseases.
Accumulation of Visceral Fat Is Positively Associated with Serum ALT and ␥ -GTP Activities in Healthy and Preclinical Middle-Aged Japanese Men
Abnormalities in metabolic parameters such as hyperglycemia and lipid levels promote the development of diabetes, metabolic syndrome and related complications such as cardiovascular disease, hypertension and inflammation in peripheral tissues (1) (2) (3) . Thus, it is necessary to identify biomarkers that can predict the development of these diseases. Recent studies have demonstrated that the circulating activity of ␥ -glutamyltransferase ( ␥ -GTP), a hepatic enzyme that is considered to represent liver injury and hepatic disorders, is a marker for inflammation and oxidative stress in healthy and preclinical subjects. This is because the circulating ␥ -GTP activity is closely associated with oxidative stress markers (e.g., lipid peroxides) and the inflammatory marker C-reactive protein (CRP) in healthy subjects in Western countries and in Japan, and because ␥ -GTP itself contributes to the production of reactive oxygen species (ROS) (4) (5) (6) (7) (8) . In addition, the circulating activity of alanine aminotransferase (ALT), another hepatic enzyme marker for liver injury, is associated with liver insulin resistance in subjects in Western countries and in Japan (9) (10) (11) . It has been reported that the circulating ␥ -GTP and ALT activities are associated with circulating CRP and lipid peroxides in healthy subjects, and that elevations in the activities of both ALT and ␥ -GTP are more strongly associated with elevated levels of circulating CRP and lipid peroxides, as compared with elevations in ALT or ␥ -GTP alone, independently of metabolic syndrome ( 4 ) . Furthermore, several studies have demonstrated that the subsequent incidence of diabetes was greater in healthy and preclinical subjects in Western and Asian countries, including Japan, with elevated circulating ␥ -GTP and/or ALT activities within the normal range, or without fatty liver or hepatic dysfunction, as compared with subjects with lower levels of these enzymes ( 9 , 12-15 ) . These results indicate that elevations in circulating ␥ -GTP and ALT activities, without fatty liver or hepatic dysfunction, in healthy and preclinical subjects may predict the future development of diabetes, metabolic syndrome and related diseases.
Recent studies have demonstrated that the accumulation of visceral fat, rather than subcutaneous fat, contributes to the development of diabetes, metabolic syn-drome and related diseases ( 16 , 17 ) . This is because visceral fat area is strongly associated with greater insulin resistance and higher levels of fasting glucose, plasma triacylglycerol and inflammatory markers such as interleukin (IL)-6 and plasminogen activator inhibitor type-1 (PAI-1), and lower levels of high-density lipoprotein (HDL)-cholesterol and adiponectin, an adipocytokine that enhances insulin sensitivity. However, it is debated whether the accumulation of visceral fat, rather than subcutaneous fat, contributes to metabolic diseases. It seems likely that increased circulating ALT and ␥ -GTP activities in healthy and preclinical subjects are associated with the accumulation of fat in adipose tissue, particularly in visceral fat. However, associations between these hepatic enzyme markers and visceral fat area in healthy and preclinical subjects have not yet been examined. Therefore, in this study, we examined the associations between serum ALT and ␥ -GTP activities and the total area of visceral and subcutaneous fat, and each region independently, in 315 healthy and preclinical Japanese men who were not taking medications for any metabolic diseases.
MATERIALS AND METHODS
Study population. We conducted a cross-sectional study of 315 healthy and preclinical men aged 40-64 y (mean Ϯ standard deviation (SD), 50.5 Ϯ 6.9 y) who participated in health check-ups at Shizuoka Medical Center (Shizuoka Prefecture, Japan) between July 2005 and March 2007. In this study, we excluded subjects with a diagnosis of metabolic diseases such as stroke, hypertension, cardiac disease, diabetes, hyperlipidemia, liver disease, kidney disease, gout or cancer, and those who were being treated with drugs for these diseases at the time of the health check-up. We regarded the participants as healthy and preclinical subjects. Anthropometric data and blood samples were collected from each participant by trained medical staff. The participants were also asked about their smoking status and physical activity. Smoking status was recorded as the number of cigarettes and duration of smoking, while self-reported physical activity was recorded as the number of physical activities performed each week. All subjects gave informed consent for the use of their personal information in this study. The study protocol was approved by the Ethics Committee of the University of Shizuoka (Shizuoka, Japan) based on the Declaration of Helsinki.
Measurements. Visceral and subcutaneous fat areas (and the total area of both regions), and waist circumference were calculated by software (N2 System Co., Ltd., Osaka, Japan) from computed tomography (CT) scans of the umbilical region, which were taken while the subjects were seated and after a light breath. Height, weight, systolic blood pressure, diastolic blood pressure, fasting serum glucose, triacylglycerol, total cholesterol, low-density lipoprotein (LDL)-cholesterol, HDL-cholesterol, aspartate aminotransferase (AST), ALT and ␥ -GTP were measured in the morning after an overnight fast. Body mass index (BMI) was calculated as weight in kilograms divided by height in meters squared. Alcohol and energy intakes during the preceding month were assessed using a brief self-administered diet history questionnaire (BDHQ) ( 18 ) . Statistical analysis. The clinical and biochemical data of the subjects are presented as means Ϯ SD. Spearman's rank correlation coefficient analyses were used to calculate the correlations for all subjects. Jonckheere-Terpstra's test was performed among three groups of subjects divided into tertiles. Multiple linear regression analyses were performed to identify the explanatory variables associated with the total visceral and subcutaneous fat area, and the variables associated with each region independently. In the multiple linear regression analyses, the natural logarithmic values of visceral and subcutaneous fat areas and the total area of both regions were used because their distributions were positively skewed. In addition, we confirmed that the explanatory variables for each response value in scatter plots showed linearity in scatter plots with the response values. All statistical analyses were performed using Excel Statistics 2008 (Social Survey Research Information Co., Ltd., Tokyo, Japan).
RESULTS
The study subjects were all healthy and preclinical Japanese men who were not taking medications for any metabolic diseases. The subjects ranged in age from 40 to 64 y (mean Ϯ SD, 50.5 Ϯ 6.9 y). The general characteristics of the subjects are shown in Table 1 . Six, 113, 28 and 28 subjects had fasting glucose Ͼ 125 mg/dL, triacylglycerol Ͼ 149 mg/dL, systolic blood pressure Ͼ 139 mmHg and diastolic blood pressure Ͼ 89 mmHg, respectively. Thirteen, 40 and 50 subjects had AST (10-40 U/L), ALT (5-45 U/L) and ␥ -GTP ( Ͻ 79 U/L) over the normal ranges.
We investigated the correlations between the total visceral and subcutaneous fat area, and each region independently with the serum clinical characteristics using Spearman's correlation coefficient analyses. The total visceral and subcutaneous fat area was positively associated with BMI, visceral fat area, subcutaneous fat area and waist circumference measured by CT scan, systolic blood pressure, diastolic blood pressure, total cholesterol, LDL-cholesterol, triacylglycerol, AST, ALT, ␥ -GTP and energy intake, and negatively associated with HDL-cholesterol. Visceral fat area was positively associated with age, BMI, total visceral and subcutaneous fat area, subcutaneous fat area and waist circumference measured by CT, systolic blood pressure, diastolic blood pressure, total cholesterol, LDL-cholesterol, triacylglycerol, AST, ALT and ␥ -GTP, and was negatively associated with HDL-cholesterol. The subcutaneous fat area was positively associated with BMI, total visceral and subcutaneous fat area, visceral fat area, waist circumference measured by CT, systolic blood pressure, diastolic blood pressure, total cholesterol, LDL-cholesterol, triacylglycerol, AST, ALT, ␥ -GTP and energy intake, and was negatively associated with HDL-cholesterol. The correlations between the fat area with blood pressure, fasting blood glucose, total cholesterol, triacylglycerol and ␥ -GTP were stronger for visceral fat area than for subcutaneous fat area. By contrast, the correlations with waist circumference, HDL-cholesterol, AST and ALT were stronger for subcutaneous fat area than for visceral fat area (Table 2 ). These associations were observed by Jonckheere-Terpstra's test among three groups divided by total visceral and subcutaneous fat area, the visceral fat area or the subcutaneous fat area (Tables 3-5) .
Based on the results of the Spearman's rank correlation coefficient analyses, we selected eight variables (age, diastolic blood pressure, fasting blood glucose, total cholesterol, triacylglycerol, AST, ALT and ␥ -GTP), which showed significant associations, and two variables related to lifestyle (alcohol intake and energy intake) for the multiple linear regression analyses. We excluded body height, BMI, waist circumference measured by CT, systolic blood pressure, LDL-cholesterol and HDL-cholesterol from the analyses because these variables were closely related to those selected for the multiple linear regression analyses. Diastolic blood pressure, ALT, ␥ -GTP, alcohol intake and energy intake were positively associated with the total visceral and subcutaneous fat area. In the analyses of visceral fat area or subcutaneous fat area, we also included the subcutaneous fat area and visceral fat area, respectively, as possible explanatory variables to adjust for the effect of each fat area on the parameters of interest. Age, subcutaneous fat area, diastolic blood pressure, ALT and ␥ -GTP were positive explanatory variables for visceral fat area. By contrast, age, visceral fat area, diastolic blood pressure, alcohol intake and energy intake were positive explanatory variables for subcutaneous fat area (Table 6) .
DISCUSSION
In the present study, we focused on the associations between the total visceral and subcutaneous fat area, and each region independently, with metabolic risk factors in healthy and preclinical Japanese middle-aged men who were not taking medications for any metabolic diseases. As shown in Table 2 , the total visceral and subcutaneous fat area and both regions indepen- dently were positively associated with blood pressure, fasting blood glucose, total cholesterol, triacylglycerol and the activities of the hepatic enzymes AST, ALT and ␥-GTP. In particular, the correlations between fat areas with diastolic blood glucose, total cholesterol and LDLcholesterol were higher with the visceral fat area than with the total visceral and subcutaneous fat area and the subcutaneous fat area. These results indicate that the accumulation of visceral fat is a stronger risk factor for metabolic diseases related to these parameters. This is consistent with previously reported results (16) . Interestingly, we observed a strong association between ALT and visceral fat or subcutaneous fat, and an association between ␥-GTP and visceral fat. Recent studies have demonstrated that higher levels of ␥-GTP and/or ALT in healthy subjects without fatty liver or hepatic dysfunction are associated with a higher incidence of diabetes compared with that in subjects with lower levels (12, 13) . Because fat accumulation, particularly visceral fat, is a strong risk factor for the development of metabolic diseases, we suggest that the accumulation of fat, particularly visceral fat, in healthy and preclinical subjects, is closely associated with circulating ALT and ␥-GTP activities. We next performed multiple linear regression analyses to explore whether the total visceral and subcutaneous fat area, and each region independently, is associated with circulating ALT and ␥-GTP activities and with other serum parameters in Japanese men without obvious metabolic diseases. As shown in Table 6 , diastolic blood pressure, circulating ALT and ␥-GTP activities, alcohol intake and energy intake were independent and positive explanatory variables for the total visceral and subcutaneous fat area. Meanwhile, the explanatory variables for visceral fat area, after adjustment for subcutaneous fat area, were age, diastolic blood pressure, and circulating ALT and ␥-GTP activities. On the other hand, the explanatory variables for subcutaneous fat area, after adjustment for visceral fat area, were age, diastolic blood pressure, alcohol intake and energy intake. These results indicate that the accumulation of visceral fat is an independent risk factor for increased circulating ALT and ␥-GTP activities and hypertension, while the accumulation of subcutaneous fat is an independent risk factor for hypertension. Many recent studies have demonstrated that the accumulation of visceral fat, rather than subcutaneous fat, contributes to the development of diabetes, metabolic syndrome and related metabolic diseases (16, 17) . Because elevated circulating ALT and ␥-GTP activities in subjects without obvious metabolic diseases are risk factors for metabolic diseases (12, 13) , the onset of metabolic diseases may be due to the accumulation of visceral fat and the subsequent elevations in circulating ALT and ␥-GTP activities. Indeed, the associations between visceral fat area and other metabolic parameters, such as diastolic blood pressure, total cholesterol and triacylglycerol, disappeared in the regression analysis. Thus, further studies, including cohort studies, should examine the nature of the relationship between visceral fat area and hepatic enzyme markers, and the subsequent development of metabolic diseases and mortality. The associations between fat areas and circulating ␥-GTP and ALT activities were specific to visceral fat. Recent studies have demonstrated that circulating ␥-GTP activity is a marker for oxidative stress and inflammation, showing associations with oxidative stress markers such as lipid peroxides and the inflammatory marker C-reactive protein (4-6). ␥-GTP is expressed on the surface of many cells, including hepatocytes, and some of the expressed enzyme is secreted into the blood. ␥-GTP is a key enzyme for glutathione (GSH) re-synthesis, catalyzing the first step in the conversion of extracellular oxidized GSH (GSSG) and GSH to cysteine and glycine, respectively, intermediates that are required for the re-synthesis of GSH. During this reaction, ␥-GTP produces ROS, such as superoxide and hydrogen peroxide (7, 8) . Indeed, higher ␥-GTP activity is found in tumor cells, and the ROS produced by ␥-GTP induce cell proliferation (8) . Furthermore, a recent study of ours showed that serum ␥-GTP activity is closely associated with plasma inflammatory cytokines such as interleukin (IL)-1␤ and IL-6 (19) , which are known to be induced by oxidative stress (20) (21) (22) . In addition, it is also known that the expression of inflammatory markers, such as IL-6 and PAI-1, is increased in visceral fat with insulin resistance (16, 17) . Collectively, these findings indicate that increased ␥-GTP activity accompanied by fat accumulation, particularly visceral fat, could be closely related to oxidative stress. Recent studies have also demonstrated that the circulating activity of ALT is associated with liver insulin resistance, which was monitored by measuring hepatic glucose output under insulin infusion, in subjects with/without impaired fasting glycemia (IFG), impaired glucose tolerance (IGT), and type 2 diabetes mellitus in Western countries and in Japan (9) (10) (11) . Several animal studies have demonstrated that ALT activity, which converts alanine to pyruvic acid and vice versa, is a rate-controlling enzyme for gluconeogenesis in the liver (23) . It is also known that insulin suppresses the expression of genes involved in gluconeogenesis, including phospho- enolpyruvate carboxykinase (PEPCK), glucose-6-phosphatase (G6P) and fructose-1,6-bisphosphatase (FBP), in mice (24) . In addition, it has been reported that insulin secretion insufficiency and hepatic insulin resistance induce gluconeogenesis and the expression of PEPCK and G6P in the liver as a result of decreased insulin activity (25) . Interestingly, it was recently demonstrated that the ALT2 gene, a subtype of ALT, is highly expressed in the liver and that its expression is induced by fatty liver and insulin resistance (26) . Thus, the positive association between the accumulation of visceral fat and ALT activity in the current study may be caused by the increased expression of these enzymes as a result of hepatic insulin resistance. These physiological changes in ␥-GTP and ALT activities in tissues, particularly in the liver, can be thus reflected by their serum activities. Further studies are needed to examine the associations between visceral fat accumulation and circulating ␥-GTP and ALT activities, and markers for inflammation and insulin resistance. We also need to acknowledge that the associations between subcutaneous fat area or visceral fat and diastolic blood pressure remained in the multiple linear regression analyses. These results indicate that the accumulation of subcutaneous and visceral fats may be an independent risk factor for hypertension. Indeed, a recent study showed that the accumulation of subcutaneous fat and visceral fat is independently associated with blood pressure in middle-aged Japanese men and women (27) . These results suggest that the accumulation of subcutaneous and visceral fat is a critical factor in the development of metabolic diseases, particularly hypertension. However, further studies are needed to examine these associations and the mechanisms involved.
In summary, visceral fat area was strongly associated with circulating ALT and ␥-GTP activities, and was independent of subcutaneous fat area, in healthy and preclinical Japanese men who were not taking medications for any metabolic diseases. Further studies are needed to examine the associations between visceral fat area and hepatic enzymes in healthy and preclinical men and women in other countries.
